LLY

797.27

+1.49%↑

JNJ

152.66

+0.35%↑

ABBV

188.71

+1.25%↑

NVO

67.78

+0.09%↑

UNH

304.72

+1.01%↑

LLY

797.27

+1.49%↑

JNJ

152.66

+0.35%↑

ABBV

188.71

+1.25%↑

NVO

67.78

+0.09%↑

UNH

304.72

+1.01%↑

LLY

797.27

+1.49%↑

JNJ

152.66

+0.35%↑

ABBV

188.71

+1.25%↑

NVO

67.78

+0.09%↑

UNH

304.72

+1.01%↑

LLY

797.27

+1.49%↑

JNJ

152.66

+0.35%↑

ABBV

188.71

+1.25%↑

NVO

67.78

+0.09%↑

UNH

304.72

+1.01%↑

LLY

797.27

+1.49%↑

JNJ

152.66

+0.35%↑

ABBV

188.71

+1.25%↑

NVO

67.78

+0.09%↑

UNH

304.72

+1.01%↑

Search

Anavex Life Sciences Corp

Open

BrancheGesundheitswesen

9.39 2.07

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

9.17

Max

9.44

Schlüsselkennzahlen

By Trading Economics

Einkommen

915K

-11M

EPS

-0.132

Angestellte

42

EBITDA

106K

-12M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+202.87% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

49M

776M

Vorheriger Eröffnungskurs

7.32

Vorheriger Schlusskurs

9.39

Nachrichtenstimmung

By Acuity

40%

60%

132 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Anavex Life Sciences Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Juni 2025, 22:09 UTC

Ergebnisse

Alimentation Couche-Tard 4Q Profit Falls on Lower Fuel Prices, Demand

25. Juni 2025, 21:19 UTC

Akquisitionen, Fusionen, Übernahmen

Solventum Removes Drinking-Water Unit From Thermo Fisher's Planned Filtration Buy

25. Juni 2025, 20:38 UTC

Ergebnisse

Micron Technology 3Q Profit Soars as AI Boom Boosts Sales

25. Juni 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears Over Middle East Ease -- Market Talk

25. Juni 2025, 23:39 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Uncertainties -- Market Talk

25. Juni 2025, 23:13 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Xero Probably Sees Value in Melio's Syndication Network -- Market Talk

25. Juni 2025, 23:13 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Equities Roundup: Market Talk

25. Juni 2025, 21:36 UTC

Ergebnisse

Jefferies' Profit Falls 40%. CEO Strikes Positive Tone on Dealmaking Outlook. -- Barrons.com

25. Juni 2025, 21:34 UTC

Ergebnisse

Jefferies' Profit Falls 40%. CEO Strikes Positive Tone on Dealmaking Outlook. -- Barrons.com

25. Juni 2025, 21:23 UTC

Ergebnisse

Micron's Profit Soars as AI Boom Boosts Sales -- Update

25. Juni 2025, 21:08 UTC

Ergebnisse

Couche-Tard 4Q Canada Same-Store Merchandise Revenues Up 3.5% >ATD.T

25. Juni 2025, 21:07 UTC

Ergebnisse

Couche-Tard 4Q U.S. Same-Store Merchandise Revenues Down 0.4% >ATD.T

25. Juni 2025, 21:05 UTC

Ergebnisse

Couche-Tard 4Q Rev $16.27B >ATD.T

25. Juni 2025, 21:05 UTC

Ergebnisse

Couche-Tard 4Q Adj EPS 46c >ATD.T

25. Juni 2025, 21:05 UTC

Ergebnisse

Couche-Tard 4Q EPS 46c >ATD.T

25. Juni 2025, 21:05 UTC

Ergebnisse

Couche-Tard 4Q Net $439.4M >ATD.T

25. Juni 2025, 20:49 UTC

Ergebnisse

Micron Reports Strong Earnings. The Stock is Up. -- Barrons.com

25. Juni 2025, 20:32 UTC

Ergebnisse

FedEx Earnings Topped Estimates. The Stock Is Fell. -- Barrons.com

25. Juni 2025, 20:27 UTC

Ergebnisse

Winnebago Stock Hits a 5-Year Low. What It Means for the RV Industry. -- Barrons.com

25. Juni 2025, 20:26 UTC

Ergebnisse

These Stocks Moved the Most Today: BP, FedEx, QuantumScape, BlackBerry, Nvidia, AeroVironment, and More -- Barrons.com

25. Juni 2025, 20:24 UTC

Ergebnisse

Micron Reports Strong Earnings. The Stock is Up. -- Barrons.com

25. Juni 2025, 20:10 UTC

Ergebnisse

Micron Reports Strong Earnings. The Stock is Up. -- Barrons.com

25. Juni 2025, 20:04 UTC

Ergebnisse

Micron Technology Sees 4Q Adj EPS $2.35-Adj EPS $2.65 >MU

25. Juni 2025, 20:04 UTC

Ergebnisse

Micron Technology Sees 4Q EPS $2.14-EPS $2.44 >MU

25. Juni 2025, 20:03 UTC

Ergebnisse

Micron Technology Sees 4Q Rev $10.4B-$11B >MU

25. Juni 2025, 20:02 UTC

Ergebnisse

Micron Technology: On Track to Deliver Record Rev With Solid Profitability and Free Cash Flow in FY25 >MU

25. Juni 2025, 20:02 UTC

Ergebnisse

Micron Technology: Record Rev in Fiscal 3Q With Growth Across End Markets >MU

25. Juni 2025, 20:01 UTC

Ergebnisse

Micron Technology 3Q Net $1.89B >MU

25. Juni 2025, 20:01 UTC

Ergebnisse

Micron Technology 3Q Adj EPS $1.91 >MU

25. Juni 2025, 20:01 UTC

Ergebnisse

Micron Technology 3Q EPS $1.68 >MU

Peer-Vergleich

Kursveränderung

Anavex Life Sciences Corp Prognose

Kursziel

By TipRanks

202.87% Vorteil

12-Monats-Prognose

Durchschnitt 28.5 USD  202.87%

Hoch 42 USD

Tief 15 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Anavex Life Sciences Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

8.275 / 9.312Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

132 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.